Patents by Inventor Jack Henkin

Jack Henkin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NANOCARRIERS HAVING SURFACE CONJUGATED PEPTIDES AND USES THEREOF FOR SUSTAINED LOCAL RELEASE OF DRUGS
    Publication number: 20220096656
    Abstract: Disclosed are biodegradable nanocarriers that have a net positive surface charge and zeta potential between about +2 to about +20 mV. The positive surface charge of the nanocarriers is provided by peptides that are covalently attached to the surface of the nanocarriers. The nanocarriers may comprise a drug and may be administered for localized and sustained delivery of the drug.
    Type: Application
    Filed: December 14, 2021
    Publication date: March 31, 2022
    Inventors: Jack Henkin, Ignacio Melgar-Asensio
  • Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection
    Patent number: 11261237
    Abstract: Disclosed are modified pigment epithelium-derived factor (PEDF) peptides, particulate carrier prodrugs thereof, and pharmaceutical compositions comprising the peptides or particulate carrier prodrugs. The peptides, particulate carrier prodrugs, and pharmaceutical compositions may be used to treat diseases and disorders that are amenable to treatment with anti-angiogenic agents, anti-tumorigenic agents, anti-fibrotic agents, chemotherapy-protecting agents, and immune stimulating agents.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: March 1, 2022
    Assignees: Northwestern University, Board of Regents of the University of Nebraska
    Inventors: Jack Henkin, Olga Volpert, Serguei Vinogradov, Ignacio Melgar-Asensio
  • Nanocarriers having surface conjugated peptides and uses thereof for sustained local release of drugs
    Patent number: 11207423
    Abstract: Disclosed are biodegradable nanocarriers that have a net positive surface charge and zeta potential between about +2 to about +20 mV. The positive surface charge of the nanocarriers is provided by peptides that are covalently attached to the surface of the nanocarriers. The nanocarriers may comprise a drug and may be administered for localized and sustained delivery of the drug.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: December 28, 2021
    Assignee: Northwestern University
    Inventors: Jack Henkin, Ignacio Melgar-Asensio
  • NANOCARRIERS HAVING SURFACE CONJUGATED PEPTIDES AND USES THEREOF FOR SUSTAINED LOCAL RELEASE OF DRUGS
    Publication number: 20200338212
    Abstract: Disclosed are biodegradable nanocarriers that have a net positive surface charge and zeta potential between about +2 to about +20 mV. The positive surface charge of the nanocarriers is provided by peptides that are covalently attached to the surface of the nanocarriers. The nanocarriers may comprise a drug and may be administered for localized and sustained delivery of the drug.
    Type: Application
    Filed: March 10, 2020
    Publication date: October 29, 2020
    Inventors: Jack Henkin, Ignacio Melgar-Asensio
  • Nanocarriers having surface conjugated peptides and uses thereof for sustained local release of drugs
    Patent number: 10583199
    Abstract: Disclosed are biodegradable nanocarriers that have a net positive surface charge and zeta potential between about +2 to about +20 mV. The positive surface charge of the nanocarriers is provided by peptides that are covalently attached to the surface of the nanocarriers. The nanocarriers may comprise a drug and may be administered for localized and sustained delivery of the drug.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: March 10, 2020
    Assignee: Northwestern University
    Inventors: Jack Henkin, Ignacio Melgar-Asensio
  • MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION
    Publication number: 20180371060
    Abstract: Disclosed are modified pigment epithelium-derived factor (PEDF) peptides, particulate carrier prodrugs thereof, and pharmaceutical compositions comprising the peptides or particulate carrier prodrugs.
    Type: Application
    Filed: September 6, 2018
    Publication date: December 27, 2018
    Inventors: Jack Henkin, Olga Volpert, Serguei Vinogradov, Ignacio Melgar-Asensio
  • Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection
    Patent number: 10081668
    Abstract: Disclosed are modified pigment epithelium-derived factor (PEDF) peptides, particulate carrier prodrugs thereof, and pharmaceutical compositions comprising the peptides or particulate carrier prodrugs. The peptides, particulate carrier prodrugs, and pharmaceutical compositions may be used to treat diseases and disorders that are amenable to treatment with anti-angiogenic agents, anti-tumorigenic agents, anti-fibrotic agents, chemotherapy-protecting agents, and immune stimulating agents.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: September 25, 2018
    Assignees: Northwestern University, Board of Regents of the University of Nebraska
    Inventors: Jack Henkin, Olga Volpert, Serguei Vinogradov, Ignacio Melgar-Asensio
  • NANOCARRIERS HAVING SURFACE CONJUGATED PEPTIDES AND USES THEREOF FOR SUSTAINED LOCAL RELEASE OF DRUGS
    Publication number: 20180092988
    Abstract: Disclosed are biodegradable nanocarriers that have a net positive surface charge and zeta potential between about +2 to about +20 mV. The positive surface charge of the nanocarriers is provided by peptides that are covalently attached to the surface of the nanocarriers. The nanocarriers may comprise a drug and may be administered for localized and sustained delivery of the drug.
    Type: Application
    Filed: November 8, 2017
    Publication date: April 5, 2018
    Applicant: Northwestern University
    Inventors: Jack Henkin, Ignacio Melgar-Asensio
  • MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION
    Publication number: 20170305998
    Abstract: Disclosed are modified pigment epithelium-derived factor (PEDF) peptides, particulate carrier prodrugs thereof, and pharmaceutical compositions comprising the peptides or particulate carrier prodrugs.
    Type: Application
    Filed: April 26, 2017
    Publication date: October 26, 2017
    Applicant: Northwestern University
    Inventors: Jack Henkin, Olga Volpert, Victor Shifrin, Serguei Vinogradov, Ignacio Melgar-Asensio
  • ANTIANGIOGENIC POLYPEPTIDES AND METHODS FOR INHIBITING ANGIOGENESIS
    Publication number: 20110218150
    Abstract: Conjugated kringle protein fragments are disclosed as compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.
    Type: Application
    Filed: March 23, 2011
    Publication date: September 8, 2011
    Applicant: Abbott Laboratories
    Inventors: Jack Henkin, Donald J. Davidson
  • Sulfonamides having antiangiogenic and anticancer activity
    Patent number: 7491718
    Abstract: Compounds having methionine aminopeptidase-2 inhibitory (MetAP2) are described. Also described are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.
    Type: Grant
    Filed: October 8, 2003
    Date of Patent: February 17, 2009
    Assignee: Abbott Laboratories
    Inventors: Kenneth M. Comess, Scott A. Erickson, Jack Henkin, Douglas M. Kalvin, Megumi Kawai, Ki H. Kim, Nwe Y. BaMaung, Chang Hoon Park, George S. Sheppard, Anil Vasudevan, Jieyi Wang, David M. Barnes, Steve D. Fidanze, Lawrence Kolaczkowski, Robert A. Mantei, David C. Park, William J. Sanders, Jason S. Tedrow, Gary T. Wang
  • Pharmaceutical formulation comprising a peptide angiogenesis inhibitor
    Patent number: 7432245
    Abstract: Parenteral formulations of peptides which are useful for sustained release are disclosed. Also disclosed are methods of preparation for the formulations.
    Type: Grant
    Filed: June 6, 2003
    Date of Patent: October 7, 2008
    Assignee: Abbott Laboratories Inc.
    Inventors: Fortuna Haviv, Bryan K. Erickson, Jack Henkin, Luk C. Li, Fanfeng Ma, Friedrich W. Richter, Yi Shi, Jingfeng Song, Siriporn Toongsuwan
  • ANTIANGIOGENIC POLYPEPTIDES AND METHODS FOR INHIBITING ANGIOGENESIS
    Publication number: 20080227701
    Abstract: Conjugated kringle protein fragments are disclosed as compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.
    Type: Application
    Filed: July 27, 2007
    Publication date: September 18, 2008
    Inventors: Jack HENKIN, Donald J. DAVIDSON
  • Antitumorigenic Drug Combination
    Publication number: 20080027008
    Abstract: Compositions comprising drugs having cooperative activity and methods of treatment using the combinations are disclosed.
    Type: Application
    Filed: July 31, 2007
    Publication date: January 31, 2008
    Inventor: Jack Henkin
  • Antitumorigenic Drug Combination
    Publication number: 20080004222
    Abstract: Compositions comprising drugs having additive antitumorigenesis activity and methods of treatment using the combinations is disclosed.
    Type: Application
    Filed: June 29, 2007
    Publication date: January 3, 2008
    Inventor: Jack Henkin
  • METHOD OF INHIBITING ANGIOGENESIS
    Publication number: 20070043089
    Abstract: Compounds having the formula are angiogenesis inhibitors. Also disclosed are compositions containing the compounds, methods of making the compounds, and methods of treatment using the compounds.
    Type: Application
    Filed: October 2, 2006
    Publication date: February 22, 2007
    Inventors: FORTUNA HAVIV, MICHAEL BRADLEY, JURGEN DINGES, DARYL SAUER, JACK HENKIN
  • METHOD OF INHIBITING ANGIOGENESIS
    Publication number: 20070032527
    Abstract: Compounds having the formula are angiogenesis inhibitors. Also disclosed are compositions containing the compounds, methods of making the compounds, and methods of treatment using the compounds.
    Type: Application
    Filed: October 2, 2006
    Publication date: February 8, 2007
    Inventors: Fortuna Haviv, Michael Bradley, Jurgen Dinges, Daryl Sauer, Jack Henkin
  • Antitumorigenic drug combination and dosing schedule
    Publication number: 20060258597
    Abstract: Compositions comprising drugs having additive antitumorigenesis activity and methods of treatment using the combinations is disclosed.
    Type: Application
    Filed: March 30, 2006
    Publication date: November 16, 2006
    Inventors: Jack Henkin, Abdullah Kherzai, Laura McKay
  • 3-Amino-2-hydroxyalkanoic acids and their prodrugs
    Patent number: 7030262
    Abstract: Compounds having the formula are useful for treating conditions which arise from or are exacerbated by angiogenesis. Also disclosed are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.
    Type: Grant
    Filed: August 6, 2003
    Date of Patent: April 18, 2006
    Assignee: Abbott Laboratories
    Inventors: Nwe Y. BaMaung, Richard A. Craig, Jack Henkin, Megumi Kawai, Xenia B. Searle, George S. Sheppard, Jieyi Wang
  • Substituted pyridines having antiangiogenic activity
    Publication number: 20060030557
    Abstract: Compounds having the formula are angiogenesis inhibitors. Also disclosed are compositions containing the compounds, methods of making the compounds, and methods of treatment using the compounds.
    Type: Application
    Filed: October 6, 2005
    Publication date: February 9, 2006
    Inventors: Fortuna Haviv, Michael Bradley, Jack Henkin, Jurgen Dinges, Daryl Sauer, Lawrence Kolaczkowski, Anil Vasudevan, David Park